Barclays analyst Gena Wang upgraded Kodiak Sciences (KOD) to Equal Weight from Underweight with a price target of $17, up from $7. The firm says Roche’s Phase 2 vamikibart plus ranibizumab data in diabetic macular edema provide “important clinical validation” Kodiak’s for KSI-101. The clinical profiles are largely comparable and key opinion leader feedback suggest a low bar for practice adoption with KSI-101, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KOD:
- Pfizer to acquire Metsera, Oracle names new CEOs: Morning Buzz
- Promising Drug Pipeline and Strong Financial Position Drive Buy Rating for Kodiak Sciences
- Kodiak Sciences initiated with a Buy at Jefferies
- Kodiak Sciences announces new data from APEX study of KSI-101
- Kodiak Sciences price target raised to $7 from $4 at Barclays